A PIPELINE POWERED BYPASSION
PUBLICATIONS AND PRESENTATIONS
Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
Journal of Medicinal Chemistry
Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X, Hwee DT, Wu Y, Wang J, Chin ER, Cremin P, Zamora J, Hartman J, Schaletzy J, Wehri E, Robertson LA, Malik FI, Morgan BP
October 4, 2021
REDWOOD-HCM: A Randomized, Double-blind, Placebo-controlled, Dose-finding Trial of the Cardiac Myosin Inhibitor, Aficamten, In Obstructive Hypertrophic Cardiomyopathy
Presentation, Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021
Maron, M, et al
Denver, CO
September 12, 2021
Effect of Omecamtiv Mecarbil in Black Patients with Heart Failure and Reduced Ejection Fraction
Presentation, Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021
Lanfear, DE, et al
Denver, CO
September 12, 2021
Clinical Diagnosis of Hypertrophic Cardiomyopathy Over Time in the United States (A Population-Based Claims Analysis)
The American Journal of Cardiology
Butzner M, Maron M, Sarocco P, et al
September 6, 2021
Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event
Journal of the American Heart Association
Carnicelli AP, Clare R, Hofmann P, Chiswell K, DeVore AD, Vemulapalli S, Felker GM, Sarocco P, Mentz RJ
September 2, 2021